The major brands in China’s urinalysis market are URIT, DIRUI, AVE, etc. URIT produced China’s first urine analyzer in 1984. And after nearly 40 years’ strenuous cultivation, it pioneered the modular urine analysis workflow using deep learning artificial intelligence (AI) image recognition technology.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

Shenzhen Mindray Bio-Medical Electronics Co., Ltd. ( “Mindray”) has agreed to acquire 75% equity interest in DiaSys Diagnostic Systems GmbH (“DiaSys”) from Gorka Holding GmbH, through Mindray Medical Netherlands B.V. (“Mindray Netherlands”), a wholly-owned subsidiary of Mindray’s wholly-owned subsidiary MR Global (HK) Limited, for an all-cash preliminary purchase price of approx. €115 million.

Recently, according to the internal announcement of Abbott Healthcare, the general manager of Abbott Electrophysiology China will be adjusted, and Liu Bei (Laura), the former senior director of Valve Therapeutics Business Unit of Edwards China, will take up this position from July 20th.

Meridian Bioscience said on Tuesday that it has received US Food and Drug Administration clearance for its Premier HpSA Flex assay for the diagnosis of Helicobacter pylori in both preserved and unpreserved stools.

Laboratory Corporation of America reported on Thursday that its second quarter revenues grew 4 percent year over year, including a 13 percent gain in its base business, which excludes COVID-19 testing revenues.

Recently, Wondfo Bio and Merck, a leading global technology company, held a globalization cooperation seminar and unanimously decided to deepen the cooperation on the basis of the pilot cooperation in the previous period, expanding the project coverage area and the population, and joining hands to enhance the accessibility of the diagnosis and treatment of thyroid diseases at the grassroots level in the world.

DiaSorin said on Thursday that its second quarter revenues fell around 12 percent year over year on a constant currency basis, as it experienced an expected continued sharp decline in COVID-19 testing, partially offset by improvements in other immunodiagnostics sales.

Excluding COVID-19 products, Group sales increase strongly by 8%1 at constant exchange rates (CER)

On the evening of July 26, Autobio announced that the company participated in the investment in Suzhou JinHe Fund as a limited partner, with a subscription amount of RMB 100 million.

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the second quarter ended July 1, 2023.

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) and QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that the companies have agreed to settle their patent dispute pending in the U.S. District Court of Delaware pursuant to a global settlement and patent cross-licensing agreement relating to digital PCR technology.